EMEA-002597-PIP08-22
Submitted by Anonymous (not verified) on 10 July 2024 - 8:34
EMEA-002597-PIP08-22
Human medicines European public assessment report (EPAR): Qalsody, Tofersen, Date of authorisation: 29/05/2024, Revision: 1, Status: Authorised
Submitted by Anonymous (not verified) on 9 July 2024 - 16:35
Human medicines European public assessment report (EPAR): Qalsody, Tofersen, Date of authorisation: 29/05/2024, Revision: 1, Status: Authorised
New Fee Regulation working arrangements
Submitted by Anonymous (not verified) on 9 July 2024 - 16:06
New Fee Regulation working arrangements
Human medicines European public assessment report (EPAR): Duloxetine Lilly, duloxetine, Date of authorisation: 08/12/2014, Revision: 10, Status: Authorised
Submitted by Anonymous (not verified) on 9 July 2024 - 14:43
Human medicines European public assessment report (EPAR): Duloxetine Lilly, duloxetine, Date of authorisation: 08/12/2014, Revision: 10, Status: Authorised
Human medicines European public assessment report (EPAR): Cymbalta, duloxetine, Date of authorisation: 17/12/2004, Revision: 33, Status: Authorised
Submitted by Anonymous (not verified) on 9 July 2024 - 14:43
Human medicines European public assessment report (EPAR): Cymbalta, duloxetine, Date of authorisation: 17/12/2004, Revision: 33, Status: Authorised
Human medicines European public assessment report (EPAR): Yentreve, duloxetine, Date of authorisation: 11/08/2004, Revision: 29, Status: Authorised
Submitted by Anonymous (not verified) on 9 July 2024 - 14:37
Human medicines European public assessment report (EPAR): Yentreve, duloxetine, Date of authorisation: 11/08/2004, Revision: 29, Status: Authorised
Human medicines European public assessment report (EPAR): Adcirca (previously Tadalafil Lilly), tadalafil, Date of authorisation: 01/10/2008, Revision: 18, Status: Authorised
Submitted by Anonymous (not verified) on 9 July 2024 - 14:20
Human medicines European public assessment report (EPAR): Adcirca (previously Tadalafil Lilly), tadalafil, Date of authorisation: 01/10/2008, Revision: 18, Status: Authorised
Human medicines European public assessment report (EPAR): Xospata, gilteritinib, Date of authorisation: 24/10/2019, Revision: 7, Status: Authorised
Submitted by Anonymous (not verified) on 9 July 2024 - 14:13
Human medicines European public assessment report (EPAR): Xospata, gilteritinib, Date of authorisation: 24/10/2019, Revision: 7, Status: Authorised
Member states contact points for review of national versions of the content of mobile scanning and other technologies
Submitted by Anonymous (not verified) on 9 July 2024 - 14:07
Member states contact points for review of national versions of the content of mobile scanning and other technologies
Nitrosamine in vivo mutagenicity workshop, European Medicines Agency, Amsterdam, the Netherlands, from 11 July 2024, 12:00 (CEST) to 12 July 2024, 15:00 (CEST)
Submitted by Anonymous (not verified) on 9 July 2024 - 13:28
Nitrosamine in vivo mutagenicity workshop, European Medicines Agency, Amsterdam, the Netherlands, from 11 July 2024, 12:00 (CEST) to 12 July 2024, 15:00 (CEST)